Diamonds and Dogs
Inching closer to a Covid-19 vaccine. AstraZeneca (AZN) is up 2% near all-time highs as the Trump Administration could grant emergency use of their coronavirus vaccine candidate as early as October, before the Presidential election, if the coronavirus vaccine shows success after its late-stage testing. The U.S. has already granted the company $1.2 billion for 300 million doses of its vaccine.
Profit-taking in another Covid-19 vaccine stock. Novavax (NVAX) is down 13% at a two-month low as the company enrolls the first volunteers in their Phase 2 COVID-19 vaccine candidate. A number of drug companies are already ahead of Novavax including Pfizer, J&J, Moderna and AstraZeneca.
Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.